Firms and researchers at odds over superhuman AI
Hype is growing from leaders of major AI companies that "strong" computer intelligence will imminently outstrip humans, but many researchers in the field see the claims as marketing spin.
The belief that human-or-better intelligence -- often called "artificial general intelligence" (AGI) -- will emerge from current machine-learning techniques fuels hypotheses for the future ranging from machine-delivered hyperabundance to human extinction.
"Systems that start to point to AGI are coming into view," OpenAI chief Sam Altman wrote in a blog post last month. Anthropic's Dario Amodei has said the milestone "could come as early as 2026".
Such predictions help justify the hundreds of billions of dollars being poured into computing hardware and the energy supplies to run it.
Others, though are more sceptical.
Meta's chief AI scientist Yann LeCun told AFP last month that "we are not going to get to human-level AI by just scaling up LLMs" -- the large language models behind current systems like ChatGPT or Claude.
LeCun's view appears backed by a majority of academics in the field.
Over three-quarters of respondents to a recent survey by the US-based Association for the Advancement of Artificial Intelligence (AAAI) agreed that "scaling up current approaches" was unlikely to produce AGI.
- 'Genie out of the bottle' -
Some academics believe that many of the companies' claims, which bosses have at times flanked with warnings about AGI's dangers for mankind, are a strategy to capture attention.
Businesses have "made these big investments, and they have to pay off," said Kristian Kersting, a leading researcher at the Technical University of Darmstadt in Germany and AAAI member.
"They just say, 'this is so dangerous that only I can operate it, in fact I myself am afraid but we've already let the genie out of the bottle, so I'm going to sacrifice myself on your behalf -- but then you're dependent on me'."
Scepticism among academic researchers is not total, with prominent figures like Nobel-winning physicist Geoffrey Hinton or 2018 Turing Prize winner Yoshua Bengio warning about dangers from powerful AI.
"It's a bit like Goethe's 'The Sorcerer's Apprentice', you have something you suddenly can't control any more," Kersting said -- referring to a poem in which a would-be sorcerer loses control of a broom he has enchanted to do his chores.
A similar, more recent thought experiment is the "paperclip maximiser".
This imagined AI would pursue its goal of making paperclips so single-mindedly that it would turn Earth and ultimately all matter in the universe into paperclips or paperclip-making machines -- having first got rid of human beings that it judged might hinder its progress by switching it off.
While not "evil" as such, the maximiser would fall fatally short on what thinkers in the field call "alignment" of AI with human objectives and values.
Kersting said he "can understand" such fears -- while suggesting that "human intelligence, its diversity and quality is so outstanding that it will take a long time, if ever" for computers to match it.
He is far more concerned with near-term harms from already-existing AI, such as discrimination in cases where it interacts with humans.
- 'Biggest thing ever' -
The apparently stark gulf in outlook between academics and AI industry leaders may simply reflect people's attitudes as they pick a career path, suggested Sean O hEigeartaigh, director of the AI: Futures and Responsibility programme at Britain's Cambridge University.
"If you are very optimistic about how powerful the present techniques are, you're probably more likely to go and work at one of the companies that's putting a lot of resource into trying to make it happen," he said.
Even if Altman and Amodei may be "quite optimistic" about rapid timescales and AGI emerges much later, "we should be thinking about this and taking it seriously, because it would be the biggest thing that would ever happen," O hEigeartaigh added.
"If it were anything else... a chance that aliens would arrive by 2030 or that there'd be another giant pandemic or something, we'd put some time into planning for it".
The challenge can lie in communicating these ideas to politicians and the public.
Talk of super-AI "does instantly create this sort of immune reaction... it sounds like science fiction," O hEigeartaigh said.
tgb/rmb

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Upturn
30 minutes ago
- Business Upturn
Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568
Tokyo, Japan and Cambridge, UK, 3 June 2025 – Nxera Pharma Co., Ltd. ('Nxera' or 'the Company'; TSE 4565) today announces that its partner, Neurocrine Biosciences ('Neurocrine') has dosed the first patient in its Phase 3 registrational program of NBI-1117568 (NBI-'568) as a potential treatment for schizophrenia, resulting in a payment of US$15 million to Nxera (Clinical Trial ID: NCT06963034). The US$15 million payment will be fully recognized as revenue in the second quarter of 2025. Nxera previously announced the initiation of the Phase 3 registrational program of NBI-'568 by Neurocrine in May 2025. The Phase 3 study is a global double-blind, placebo-controlled trial evaluating NBI-'568 in adults with a primary diagnosis of schizophrenia who are experiencing an acute exacerbation or relapse of symptoms. The study is expected to enroll approximately 280 patients. The primary endpoint of the study is a reduction from baseline in the Positive and Negative Syndrome Scale (PANSS). The key secondary endpoint is improvement in the Clinical Global Impression of Severity (CGI-S) scale. –END– About Nxera Pharma Nxera Pharma is a technology powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. We have built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high value, large and growing market and those in the broader APAC region. Behind that, and powered by our unique NxWave™ discovery platform, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline of potentially first- and best-in-class candidates is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across neurology/neuropsychiatry, metabolic diseases and immunology and inflammation. Nxera employs approximately 400 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565). For more information, please visit LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma Enquiries: Nxera – Media and Investor RelationsShinya Tsuzuki, VP, Head of Investor RelationsShinichiro Nishishita, VP Investor Relations, Head of Regulatory DisclosuresMaya Bennison, Communications Manager +81 (0)3 5962 5718 | +44 (0)1223 949390 |[email protected]
Yahoo
33 minutes ago
- Yahoo
Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568
Tokyo, Japan and Cambridge, UK, 3 June 2025 – Nxera Pharma Co., Ltd. ('Nxera' or 'the Company'; TSE 4565) today announces that its partner, Neurocrine Biosciences ('Neurocrine') has dosed the first patient in its Phase 3 registrational program of NBI-1117568 (NBI-'568) as a potential treatment for schizophrenia, resulting in a payment of US$15 million to Nxera (Clinical Trial ID: NCT06963034). The US$15 million payment will be fully recognized as revenue in the second quarter of 2025. Nxera previously announced the initiation of the Phase 3 registrational program of NBI-'568 by Neurocrine in May 2025. The Phase 3 study is a global double-blind, placebo-controlled trial evaluating NBI-'568 in adults with a primary diagnosis of schizophrenia who are experiencing an acute exacerbation or relapse of symptoms. The study is expected to enroll approximately 280 patients. The primary endpoint of the study is a reduction from baseline in the Positive and Negative Syndrome Scale (PANSS). The key secondary endpoint is improvement in the Clinical Global Impression of Severity (CGI-S) scale. –END– About Nxera PharmaNxera Pharma is a technology powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. We have built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high value, large and growing market and those in the broader APAC region. Behind that, and powered by our unique NxWave™ discovery platform, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline of potentially first- and best-in-class candidates is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across neurology/neuropsychiatry, metabolic diseases and immunology and inflammation. Nxera employs approximately 400 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565). For more information, please visit LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma Enquiries: Nxera – Media and Investor RelationsShinya Tsuzuki, VP, Head of Investor RelationsShinichiro Nishishita, VP Investor Relations, Head of Regulatory DisclosuresMaya Bennison, Communications Manager+81 (0)3 5962 5718 | +44 (0)1223 949390 |IR@ MEDiSTRAVA (for International Media)Mark Swallow, Frazer Hall, Erica Hollingsworth+44 (0)203 928 6900 | Nxera@ Forward-looking statements This press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group's actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise

Yahoo
an hour ago
- Yahoo
Console raises $6.2M from Thrive to free IT teams from mundane tasks with AI
If you've ever been locked out of your work computer, you know the urgent need to reach IT support. Unfortunately, help desk staff are often busy assisting others, which can mean a significant delay before you regain access. Andrei Serban realized the critical importance of IT's manual work when he was a product lead on Rippling's apps and integrations team. Serban, who joined Rippling after it acquired his coding security startup Fuzzbuzz in 2023, saw an opportunity to automate many of the help desk's basic tasks with AI, from resetting passwords, to granting access to apps like Figma and Miro, to routine troubleshooting. Serban couldn't wait to get started on his vision. He left Rippling last year to found Console, a startup on a mission to help IT teams reduce mundane, repetitive tasks, thereby freeing up time for help desk professionals to work on more strategic and sophisticated projects. While trying to automate help desk functions isn't new, Console differentiates itself from existing competitors — including Moveworks, which was acquired by ServiceNow in March for $2.85 billion — by forgoing long, complex installation processes. Thanks to its easy integration with Slack, Console's AI assistant can be made available to everyone in the company in just a few weeks. "We're able to get there so fast because we don't require you to replace your help desk," he said. Console sees itself as an AI co-worker that up-levels existing help desk professionals. Serban even suggested that as companies digitize more of their operations, the IT function will become increasingly vital. Employees message Console on Slack and the startup's AI agent quickly responds to requests because it knows everything about the user, from their specific laptop model to the applications they have permission to use. Console's AI can resolve over 50% of the tasks on its own, and it will loop in someone from IT for more complex issues, Serban said. The fast install time attracted customers, including Scale AI, Flock Safety, and Calendly. These customer wins have led Console to secure $6.2 million in seed funding from Thrive Capital. Vince Hankes, a partner at Thrive, said that the firm, which has backed many of the leading AI companies, including OpenAI, Cursor, and ElevenLabs, has had a thesis about artificial intelligence's potential to assist with IT tasks since ChatGPT was first released in the fall of 2022. While Hankes acknowledged that Console's fast integration might make it seem easily replaceable, he believes its AI technology will improve so quickly with user adoption that it will become an indispensable, deeply integrated system essential to everyone at the customer's company. Console's goal is to eventually start supporting other functions, including answering employee requests about HR, finance, and legal. "We want Console to be an employee's first call for help," Serban said. This article originally appeared on TechCrunch at Sign in to access your portfolio